AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30462182 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin monotherapy
Number of subjects: 266
Study 30462182 — intervention group
Group type: COMPARATOR
Intervention: Colistin-meropenem combination therapy
Number of subjects: 266
Study 30462182 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin resistant (CoR) isolates
Number of subjects: 266
Study 30462182 — intervention group
Group type: COMPARATOR
Intervention: Colistin susceptible (CoS) isolates
Number of subjects: 266
Study 28244612 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea tablets
Number of subjects: 45
Study 28244612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 24970794 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted oral anticoagulation (UAC)
Number of subjects: 573
Study 24970794 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy (BT)
Number of subjects: 573
Study 24262616 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush stenting
Number of subjects: 424
Study 24262616 — intervention group
Group type: COMPARATOR
Intervention: Culotte stenting
Number of subjects: 424
Study 21941091 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX (refrigerator-stable formulation), single dose administered within 6 months of expiry
Number of subjects: 2
Study 19888523 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin
Number of subjects: 15
Study 19888523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin
Number of subjects: 15
Study 19888523 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 16520474 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (150 mg/d for 12 months)
Number of subjects: 30
Study 16520474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15486520 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 75 mg daily
Number of subjects: 66
Study 15486520 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 150 mg daily
Number of subjects: 66
Study 10202747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-Cerv intravaginally for two weeks after LEEP
Number of subjects: 48
Study 10202747 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (Control)
Number of subjects: 48
Study 7799026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) 750 mg orally twice per day
Number of subjects: 146
Study 7799026 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMS) 160 mg trimethoprim and 800 mg sulfamethoxazole orally twice per day
Number of subjects: 146
Study 7799026 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMS)
Number of subjects: 146
Study 2191113 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 31
Study 2191113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 87620 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine combined with domeperidone (peripheral dopamine receptor blocker)
Number of subjects: 4
Study 87620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30661553 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 58
Study 30661553 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 58
Study 28203735 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA
Number of subjects: 95
Study 28203735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 24218041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreous samples from eyes with RRD
Number of subjects: 117
Study 24218041 — intervention group
Group type: COMPARATOR
Intervention: Vitreous samples from eyes with macular hole or pucker
Number of subjects: 117
Study 22653067 — intervention group
Group type: EXPERIMENTAL
Intervention: Eugenol concentrations at or below the International Fragrance Association standard
Number of subjects: 0
Study 22653067 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19902745 — intervention group
Group type: EXPERIMENTAL
Intervention: Single carbon fiber cage (group A)
Number of subjects: 97
Study 19902745 — intervention group
Group type: COMPARATOR
Intervention: Double carbon fiber cages (group B)
Number of subjects: 97
Study 17252567 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (Photodynamic Therapy) with MAL (16% methyl aminolevulinate)
Number of subjects: 30
Study 17252567 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL (Intense Pulsed Light)
Number of subjects: 30
Study 17252567 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15916891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg bd
Number of subjects: 160
Study 15916891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs bd)
Number of subjects: 160
Study 11843370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (500 mL of normal saline over 30 minutes)
Number of subjects: 200
Study 11843370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 200
Study 11843370 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 200
Study 9863486 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 40 mg after placebo
Number of subjects: 30
Study 9863486 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 40 mg after atropine
Number of subjects: 30
Study 9863486 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 40 mg after sumatriptan
Number of subjects: 30
Study 9863486 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 200 mg after atropine
Number of subjects: 30
Study 9863486 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 200 mg after sumatriptan
Number of subjects: 30
Study 8543964 — intervention group
Group type: EXPERIMENTAL
Intervention: EPV of 2
Number of subjects: 673
Study 8543964 — intervention group
Group type: EXPERIMENTAL
Intervention: EPV of 5
Number of subjects: 673
Study 8543964 — intervention group
Group type: EXPERIMENTAL
Intervention: EPV of 10
Number of subjects: 673
Study 8543964 — intervention group
Group type: EXPERIMENTAL
Intervention: EPV of 15
Number of subjects: 673
Study 8543964 — intervention group
Group type: EXPERIMENTAL
Intervention: EPV of 20
Number of subjects: 673
Study 8543964 — intervention group
Group type: EXPERIMENTAL
Intervention: EPV of 25
Number of subjects: 673
Study 8543964 — intervention group
Group type: EXPERIMENTAL
Intervention: Original analysis with 36 events per variable
Number of subjects: 673
Study 8543964 — intervention group
Group type: EXPERIMENTAL
Intervention: Original analysis
Number of subjects: 673
Study 2229750 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 2099
Study 2229750 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2099
Study 2229750 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy in patients with proximal left anterior descending coronary artery stenosis ≥ 70% and ejection fraction < 0.50
Number of subjects: 2099
Study 2229750 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy in patients with three vessel coronary artery disease and ejection fraction < 0.50
Number of subjects: 2099
Study 7410724 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (expectancy condition)
Number of subjects: 72
Study 7410724 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic beverage (control condition)
Number of subjects: 72
Study 31538453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlo‐SITE (chlorhexidine based local drug delivery) applied in 1 pocket in 2 quadrants after full mouth disinfection
Number of subjects: 60
Study 31538453 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment in 2° and 3° quadrants)
Number of subjects: 60
Study 27902641 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (50 μg/kg)
Number of subjects: 18
Study 27902641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 18
Study 27902641 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine followed by Sugammadex (50 μg/kg neostigmine, then 2 mg/kg sugammadex after 3 min)
Number of subjects: 18
Study 25710559 — intervention group
Group type: EXPERIMENTAL
Intervention: HICE (20 min cycling @ just above ventilatory threshold)
Number of subjects: 13
Study 25710559 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE (10 X 1‐min @ ∼90% peak aerobic power)
Number of subjects: 13
Study 25710559 — intervention group
Group type: EXPERIMENTAL
Intervention: HICE
Number of subjects: 13
Study 25710559 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE
Number of subjects: 13
Study 25710559 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 23373541 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered SEMS
Number of subjects: 68
Study 23373541 — intervention group
Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 68
Study 23373541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of SEMS
Number of subjects: 68
Study 21275083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training for schizophrenia patients (MCT+)
Number of subjects: 48
Study 21275083 — intervention group
Group type: COMPARATOR
Intervention: Cognitive remediation (active control)
Number of subjects: 48
Study 19615696 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNbeta) treatment
Number of subjects: 2570
Study 17302058 — intervention group
Group type: EXPERIMENTAL
Intervention: Wendan Tablet (WT)
Number of subjects: 43
Study 17302058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 16830065 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 47
Study 16830065 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 47
Study 12765886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg kg(‐1))
Number of subjects: 40
Study 12765886 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 11104345 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratentorial radiation dose of 25 Gy
Number of subjects: 36
Study 11104345 — intervention group
Group type: COMPARATOR
Intervention: Supratentorial radiation dose of 35 Gy
Number of subjects: 36
Study 8675231 — intervention group
Group type: EXPERIMENTAL
Intervention: alfa 2a interferon
Number of subjects: 30
Study 8675231 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 1651860 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1, plus 250 mg/day on days 2-5)
Number of subjects: 110
Study 1651860 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (625 mg every eight hours for ten days)
Number of subjects: 110
Study 7042074 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptichemio (75-100 mg/m2 IV q 3-4 weeks)
Number of subjects: 56
Study 7042074 — intervention group
Group type: COMPARATOR
Intervention: L-PAM (30-40 mg/m2 IV q 3-4 weeks)
Number of subjects: 56
Study 31658494 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 12
Study 31658494 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin
Number of subjects: 12
Study 31658494 — intervention group
Group type: COMPARATOR
Intervention: Intravenous salbutamol
Number of subjects: 12
Study 31658494 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin
Number of subjects: 12
Study 31360729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus ramosetron (group R, n=49)
Number of subjects: 110
Study 31360729 — intervention group
Group type: COMPARATOR
Intervention: Tramadol only (group N, n=51)
Number of subjects: 110
Study 28882926 — intervention group
Group type: EXPERIMENTAL
Intervention: ProAsk intervention delivered on a tablet device
Number of subjects: 88
Study 28882926 — intervention group
Group type: EXPERIMENTAL
Intervention: ProAsk intervention
Number of subjects: 88
Study 24975366 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (single-dose, two-period crossover study)
Number of subjects: 70
Study 23388524 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-led groups (TLG)
Number of subjects: 99
Study 23388524 — intervention group
Group type: COMPARATOR
Intervention: Self-help groups (SHG)
Number of subjects: 99
Study 21501328 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once a day for 12 weeks
Number of subjects: 48
Study 21501328 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg once a day for 12 weeks
Number of subjects: 48
Study 21501328 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 48
Study 21501328 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 48
Study 19709754 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, 10 mg
Number of subjects: 375
Study 19709754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 375
Study 19709754 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of escitalopram and bupropion
Number of subjects: 375
Study 17393613 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-stimulation plus chlorimipramine (PS+Chl)
Number of subjects: 60
Study 17393613 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine (Chl)
Number of subjects: 60
Study 15117326 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b plus ribavirin (RBV) 1000-1200 mg/day for 48 weeks (Study 1)
Number of subjects: 677
Study 15117326 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b plus ribavirin (RBV) 1000-1200 mg/day for 4 weeks followed by three times weekly dosing for 44 weeks (Study 2)
Number of subjects: 677
Study 15117326 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV dose reduction
Number of subjects: 677
Study 15117326 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b daily use
Number of subjects: 677
Study 15117326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (Women vs Men)
Number of subjects: 677
Study 15117326 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors (creatinine clearance, Hb levels, age)
Number of subjects: 677
Study 15117326 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline weight
Number of subjects: 677
Study 11208843 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week chemotherapy regimen (vincristine and actinomycin D)
Number of subjects: 382
Study 11208843 — intervention group
Group type: COMPARATOR
Intervention: 8-week chemotherapy regimen (vincristine and actinomycin D)
Number of subjects: 382
Study 11208843 — intervention group
Group type: EXPERIMENTAL
Intervention: No further treatment (NFT) for stage I favorable histology (n = 5)
Number of subjects: 382
Study 11208843 — intervention group
Group type: EXPERIMENTAL
Intervention: VCR and AMD for 17 weeks (AV) for stage I standard histology or anaplasia (n = 244)
Number of subjects: 382
Study 11208843 — intervention group
Group type: EXPERIMENTAL
Intervention: VCR, AMD, and anthracycline for 27 weeks (AVE) for stages II and III (n = 75)
Number of subjects: 382
Study 11208843 — intervention group
Group type: EXPERIMENTAL
Intervention: VCR, AMD, anthracycline, and ifosfamide for 36 weeks (DEVI) for anaplastic tumors staged higher than I (n = 14)
Number of subjects: 382
Study 11208843 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE with 15-Gy abdominal irradiation (RTH) for stages IIN1 and III (n = 56)
Number of subjects: 382
Study 9777135 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 9777135 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0
Study 9777135 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 7883388 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg t.i.d. intravenously for 3-21 days (mean 5.4 days)
Number of subjects: 109
Study 7883388 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg t.i.d. intravenously for 3-17 days (mean 5.1 days)
Number of subjects: 109
Study 3284283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine chewing gum (n = 62)
Number of subjects: 172
Study 3284283 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine chewing gum (n = 54)
Number of subjects: 172
Study 3284283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counselling with nicotine gum (2 mg or 4 mg)
Number of subjects: 172
Study 3284283 — intervention group
Group type: COMPARATOR
Intervention: Advice only control group (n = 56)
Number of subjects: 172
Study 3284283 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported chronic bronchitis subgroup
Number of subjects: 172
Study 31999399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education combined with the provision of complementary foods
Number of subjects: 243
Study 31999399 — intervention group
Group type: COMPARATOR
Intervention: Baseline data
Number of subjects: 243
Study 31999399 — intervention group
Group type: COMPARATOR
Intervention: Endline data
Number of subjects: 243
Study 30076593 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted GenerationPMTO® intervention for Latino/a immigrant families
Number of subjects: 39
Study 28272164 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Number of subjects: 663
Study 28272164 — intervention group
Group type: COMPARATOR
Intervention: FTC/TDF
Number of subjects: 663
Study 25528415 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel emergency contraception
Number of subjects: 1731
Study 23085475 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction (select a healthy meal)
Number of subjects: 124
Study 23085475 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction + Information (select a healthy meal with nutrition information)
Number of subjects: 124
Study 23085475 — intervention group
Group type: COMPARATOR
Intervention: Control (served normally)
Number of subjects: 124
Study 21115872 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan Weekly (Tw) 4 mg/m²/week administered on days 1, 8, and 15
Number of subjects: 194
Study 21115872 — intervention group
Group type: COMPARATOR
Intervention: Conventional 5-Day Schedule (Tc) 1.25 mg/m²/day on days 1 to 5
Number of subjects: 194
Study 21115872 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan Weekly (Tw)
Number of subjects: 194
Study 19286582 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin daily
Number of subjects: 94
Study 19286582 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 94
Study 16854404 — intervention group
Group type: EXPERIMENTAL
Intervention: Recutin (100 mg)
Number of subjects: 24
Study 16854404 — intervention group
Group type: COMPARATOR
Intervention: Polybutin (100 mg)
Number of subjects: 24
Study 15264961 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling curriculum
Number of subjects: 26
Study 15264961 — intervention group
Group type: COMPARATOR
Intervention: Control group (initial control before intervention crossover)
Number of subjects: 26
Study 12136489 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ID)
Number of subjects: 105
Study 12136489 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomin
Number of subjects: 105
Study 10451042 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute low-back pain patients
Number of subjects: 180
Study 10451042 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 180
Study 8665993 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY t 7207 (20 mg)
Number of subjects: 8
Study 2225152 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5% eye drops administered three times a day from the day prior to operation to the 10th day after operation
Number of subjects: 0
Study 2225152 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times a day from the day prior to operation to the 10th day after operation
Number of subjects: 0
Study 342962 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 39
Study 342962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28267947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™
Number of subjects: 100
Study 28267947 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme™ Second Seal™
Number of subjects: 100
Study 25546164 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose/metformin fixed-dose combination (FDC)
Number of subjects: 28
Study 25546164 — intervention group
Group type: COMPARATOR
Intervention: Coadministered individual voglibose and metformin tablets
Number of subjects: 28
Study 23690755 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation of local stakeholder groups (laywomen facilitated monthly meetings for 3 years)
Number of subjects: 90
Study 23690755 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation of local stakeholder groups
Number of subjects: 90
Study 23690755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no facilitation of local stakeholder groups)
Number of subjects: 90
Study 22215335 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (16 weeks, including warm-up, aerobic exercises on standing cycles, resistance exercises with Thera-Band)
Number of subjects: 15
Study 22215335 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 15
Study 19139323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored letter and enhanced management
Number of subjects: 599
Study 19139323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontailored letter and enhanced management
Number of subjects: 599
Study 19139323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored letter and nonenhanced management
Number of subjects: 599
Study 19139323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontailored letter and nonenhanced management
Number of subjects: 599